» Articles » PMID: 28445952

SOCS3 Inhibits the Pathological Effects of IL-22 in Non-melanoma Skin Tumor-derived Keratinocytes

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Apr 28
PMID 28445952
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Basal cell carcinomas (BCC) and squamous-cell carcinomas (SCC) are common malignancies in humans, caused by neoplastic transformation of keratinocytes of the basal or suprabasal layers of epidermis, respectively. Tumor-infiltrating lymphocytes (TILs) are frequently found in BCC and SCC, and functionally promote epithelial carcinogenesis. TILs secreting IL-22, in particular, participate to BCC and SCC growth by inducing keratinocyte proliferation and migration, as well as the expression of inflammatory, anti-apoptotic and pro-angiogenic genes.In this study, we identified SOCS3 as a valid candidate to be manipulated for suppressing tumorigenic functions in BCC and SCC. We found that SOCS3 and SOCS1 expression was reduced in vivo, in tumor lesions of BCC and SCC, as compared to other skin inflammatory conditions such as psoriasis, despite the high number of IL-22-secreting TILs. Moreover, IL-22 was not able to induce in vitro the transcriptional expression of SOCS3 in BCC-or SCC-derived keratinocytes, contrarily to healthy cells. Aimed at rescuing SOCS3 activity in these tumor contexts, a SOCS3-derived peptide, named KIR-ESS, was synthesized, and its ability in suppressing IL-22-induced responses was evaluated in healthy and transformed keratinocytes. We found that KIR-ESS peptide efficiently suppressed the IL-22 molecular signaling in keratinocytes, by acting on STAT3 and Erk1/2 cascade, as well as on the expression of STAT3-dependent downstream genes. Interestingly, after treatment with peptide, both healthy and transformed keratinocytes could no longer aberrantly proliferate and migrate in response to IL-22. Finally, treatment of athymic nude mice bearing SCC xenografts with KIR-ESS peptide concomitantly reduced tumor growth and activated STAT3 levels. As a whole, these data provides the rationale for the use in BCC and SCC skin tumors of SOCS3 mimetics, being able to inhibit the deleterious effects of IL-22 in these contexts.

Citing Articles

The role of IL-22 in cancer.

Hunzeker Z, Zhao L, Kim A, Parker J, Zhu Z, Xiao H Med Oncol. 2024; 41(10):240.

PMID: 39231878 DOI: 10.1007/s12032-024-02481-8.


PEGylated SOCS3 Mimetics Encapsulated into PLGA-NPs as Selective Inhibitors of JAK/STAT Pathway in TNBC Cells.

La Manna S, Cugudda A, Mercurio F, Leone M, Fortuna S, Di Natale C Int J Nanomedicine. 2024; 19:7237-7251.

PMID: 39050870 PMC: 11268778. DOI: 10.2147/IJN.S441205.


Are peptidomimetics the compounds of choice for developing new modulators of the JAK-STAT pathway?.

Cugudda A, La Manna S, Marasco D Front Immunol. 2024; 15:1406886.

PMID: 38983855 PMC: 11232365. DOI: 10.3389/fimmu.2024.1406886.


SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.

Morelli M, Madonna S, Albanesi C Front Immunol. 2024; 15:1393799.

PMID: 38975347 PMC: 11224294. DOI: 10.3389/fimmu.2024.1393799.


Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells.

Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M Nat Commun. 2024; 15(1):2839.

PMID: 38565563 PMC: 10987549. DOI: 10.1038/s41467-024-46540-0.


References
1.
Bauman J, Eaton K, Martins R . Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007; 143(7):889-92. DOI: 10.1001/archderm.143.7.889. View

2.
Galer C, Corey C, Wang Z, Younes M, Gomez-Rivera F, Jasser S . Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck. 2010; 33(2):189-98. PMC: 3010504. DOI: 10.1002/hed.21419. View

3.
Madonna S, Scarponi C, Sestito R, Pallotta S, Cavani A, Albanesi C . The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Krüppel-like factor-4, and it is dysregulated in psoriatic.... J Immunol. 2010; 185(4):2467-81. DOI: 10.4049/jimmunol.1001426. View

4.
Madonna S, Scarponi C, Pallotta S, Cavani A, Albanesi C . Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis. Cell Death Dis. 2012; 3:e334. PMC: 3388239. DOI: 10.1038/cddis.2012.69. View

5.
Wolk K, Witte E, Witte K, Warszawska K, Sabat R . Biology of interleukin-22. Semin Immunopathol. 2010; 32(1):17-31. DOI: 10.1007/s00281-009-0188-x. View